News

Bigbank AS Reports Solid Performance Metrics for October

Bigbank AS Reports Solid Performance Metrics for October

Bigbank AS Sees Positive Growth in October

Bigbank has enjoyed a stable month, highlighting a positive trajectory in both loan and deposit portfolios, which underpins its robust profitability.

During October, the bank's loan portfolio expanded by an impressive 34 million euros, culminating in a total of 2.6 billion euros by month’s end. The surge was propelled by business loans, which rose by 16 million euros, alongside home loans that experienced an increase of 18 million euros. Notably, the consumer loan segment plateaued, maintaining its stature at the end of September.

The deposit portfolio likewise saw a significant uptick, climbing by 44 million euros in October. Amidst a stabilizing interest rate landscape, the 6-month Euribor has shown a marginal upward trend recently, resulting in higher rates for long-term deposits and stimulating customer interest. This growth was primarily fueled by the term deposit sector, which advanced by 24 million euros, while savings deposits increased by 16 million euros.

In an exciting development, Bigbank introduced current accounts for retail customers in Latvia during October. Latvian clientele can now take advantage of competitive conditions similar to those enjoyed by customers in Estonia and Lithuania. Here, clients are delighted to earn 2% annual interest on their idle funds, with all transaction fees waived. The aggregate balance of current accounts further swelled by 3 million euros, reaching a commendable 12 million euros by month’s conclusion.

Positive Financial Outcomes Amidst Competitive Landscape

The stabilizing interest rates have eased the pressure on net interest income, allowing for a more favorable comparison in year-on-year interest income figures. This shift is gradually being driven by the ongoing expansion of the loan portfolio. In the first ten months, net interest income climbed by 2.3 million euros compared to last year, evidencing a resilient financial strategy.

Bigbank’s loan portfolio maintains high credit quality, with a marked decrease in net allowances for expected credit losses and provision expenses, down 8.8 million euros or 47% compared to the corresponding timeframe last year. The significant enhancement in payment performance across consumer loans in all three Baltic nations has positively influenced these statistics. Fortunately, the share of non-performing loans remains stable at 4.5%.

Moreover, October's net profit amounted to a formidable 3.1 million euros. This gain is attributed not only to the growth in net interest income, but also a noteworthy increase in net fee income, which rose by 1.2 million euros over the prior ten-month period.

Opportunities and Challenges Ahead

As of month-end, Bigbank's workforce totaled 624 employees. The company has seen team expansion and salary increments contributing to an increase of 5.7 million euros in salary costs over the past ten months relative to the previous year. However, there was a rise in income tax obligations, climbing by 1.9 million euros, which resulted from increased tax rates recently instituted in Estonia and Lithuania.

Key Financial Indicators for October 2025

Some key performance metrics include:

  • Customer deposits and loans received increased by 422 million euros year-on-year, reaching a total of 2.8 billion euros (+18%).
  • Loans to customers grew by 511 million euros year-on-year, reaching 2.6 billion euros (+24%).
  • Net interest income amounted to 9.4 million euros in October, with the cumulative ten-month total hitting 88.1 million euros, reflecting a year-on-year increase of 2.3 million euros (+3%).
  • Net allowance for expected credit losses and provision expenses aggregated to 10.1 million euros in the first ten months of the year, which is down 8.8 million euros or 47% year-on-year.
  • Net profit for October stood at 3.1 million euros, contributing to a cumulative profit of 33.3 million euros over the first ten months, a rise of 3.1 million euros or 10% compared to last year.
  • Return on equity for October was recorded at 12.5%.

Insights and Adjustments

Comparative data from October 2024 showed that both net interest income and net allowance for expected credit losses have been adjusted downwards by 2.5 million euros. This adjustment rectified an error in the calculation of interest income where it was improperly based on gross instead of net figures for impaired financial assets. Notably, this adjustment has no impact on the net profit reported for October 2024.

Bigbank AS (Tallinn:BIGB080032A) has more than 30 years of operational history and stands as a commercial bank under Estonian ownership. At the end of October 2025, the bank reported total assets amounting to 3.2 billion euros and equity of 295 million euros. Operating across nine nations, Bigbank proudly serves over 178,000 active customers, employing a workforce of more than 600 individuals. Moody's has awarded Bigbank a long-term bank deposit rating of Ba1, complemented by a baseline credit assessment and an adjusted BCA of Ba2.

For further inquiries, please contact:

Argo Kiltsmann
Member of the Management Board
Telephone: +372 5393 0833
Email: argo.kiltsmann@bigbank.ee

For more information, please visit www.bigbank.eu.

Frequently Asked Questions

1. What were Bigbank's net profits for October 2025?

The net profit for October 2025 was reported at 3.1 million euros.

2. How much did the loan portfolio grow in October?

The loan portfolio grew by 34 million euros, totaling 2.6 billion euros.

3. How has Bigbank's deposit portfolio changed?

The deposit portfolio increased by 44 million euros during October.

4. What is Bigbank's return on equity for October?

Return on equity for October 2025 stood at 12.5%.

5. How many employees does Bigbank have?

As of the end of October 2025, Bigbank employed 624 individuals.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Hims & Hers Faces Securities Lawsuit Amid Stock Dive

Updated Category News Views 0

Hims & Hers Takes a Hit Right out of the gate, we're seeing Hims & Hers Health, Inc. (NYSE:HIMS) embroiled in a securities class action, thanks to some good old-fashioned alleged corporate shenanigans. It's one of those times where you'd cock an eyebrow and say, "What in the world were they thinking?" The FTC has slapped them with accusations of misleading privacy claims...

Continue Reading
Ruth, Mickey, Superman: Morphy's Auction Smorgasbord

Updated Category News Views 4

A Surreal Gathering of Icons and Memorabilia Who'd have thought you could snag both Babe Ruth and Mickey Mouse in one fell swoop? Well, come November 10-12, 2026, fans and collectors alike will have the opportunity at Morphy Auctions in Denver, PA. It's a dizzying array of Americana where cultural legend meets sports royalty, and we're not talking pocket change here. Babe...

Continue Reading
Pathalys' Phase 3 Data Shows Promise for CKD Drug

Updated Category News Views 24

A Glimpse at Pathalys Pharma's Recent Win This is some groundbreaking stuff emerging from Pathalys Pharma. Their investigational drug, upacicalcet, has just clinched a significant victory in two crucial Phase 3 trials - PATH-1 and PATH-2 - aimed at treating Secondary Hyperparathyroidism (SHPT) in patients with end-stage kidney disease undergoing hemodialysis. With SHPT...

Continue Reading
Roadrunner's Bold Move: New LTL Service and Rate Hike

Updated Category News Views 3

When you shake up the status quo in logistics, you better be ready for the ride. Roadrunner Freight is doing just that with the launch of its first-ever outbound Canada-to-U.S. LTL service. They're shaking up a market that's been bogged down with inefficiencies for far too long. This isn't just another lane to add to a map; it's a new passage for Canadian goods, paving a...

Continue Reading
Invisors Expands PayBill Suite for Staffing Efficiency

Updated Category News Views 4

Invisors Doubles Down on Workday Integration The winds of change are whispering in the Professional & Business Services sector as Invisors rolls out its enhanced PayBill Suite. This move isn't just another tick on some corporate checklist; it's a serious play to streamline the gnarly process of transitions that staffing firms face. Invisors is tying this suite tightly...

Continue Reading
FP Movement Opens Energizing Boutique in Cranston, RI

Updated Category News Views 23

FP Movement Expands with Style in Rhode Island FP Movement is shaking things up in Cranston, Rhode Island, bringing its signature activewear vibe to Garden City Center with a new shop. It’s not just about buying leggings anymore; it’s about diving into a lifestyle that screams energy and community spirit. The store, which spans 1,209 selling-square-feet, opened its...

Continue Reading
FDA Nod for Subcutaneous SKYRIZI in Crohn's Disease

Updated Category News Views 23

AbbVie's Injection Makes Waves in Crohn's Treatment Here's a bit of medicine shake-up for you. AbbVie just snagged FDA approval for its subcutaneous SKYRIZI—specifically designed for adults battling moderately to severely active Crohn's disease. This news isn't just a blip on the radar; it's significant for patients and the healthcare landscape. We're talking about new...

Continue Reading
JJ Lin's Iconic Singapore Grand Prix Show With 20 Songs

Updated Category News Views 3

Nothing beats the thrill of a live performance under a night sky, with the adrenaline of a Formula 1 race still in the air. On October 9, 2026, Mandopop superstar JJ Lin captivated the crowd at the Padang Stage of the Singapore Grand Prix, delivering not just a concert but a spectacle of international scale. Stage Spectacle with Precision JJ Lin took control like a...

Continue Reading
York Space Systems Class Action: Deadline Approaches

Updated Category News Views 26

Rapid Deadline: October 30 Looms for York Space Systems You blink, and you might miss the deadline. We’re just a step away from deadline day in the York Space Systems’ class action lawsuit. If you've got skin in this game, time's not on your side. Shareholders, particularly those who hopped on the York Space train via their IPO back in January 2026, are staring down...

Continue Reading
ASPR AI Unveils Private Sales Agent Studio

Updated Category News Views 11

Pushing Sales AI Into a Secure Future Picture a world where your most sensitive sales data stays safely behind your own digital doors. ASPR AI is shaking up the game by launching its Private Sales Agent Studio, a move that catapults enterprise sales management into a new era of control and customization. Why Private Means Business Here's the meat of it: sales AI usually...

Continue Reading

Top 5 Most Recently Viewed Articles

MediaAlpha Set for Q3 2024 Financial Results Presentation

Updated Category News Views 78

MediaAlpha's Upcoming Financial Report Announcement MediaAlpha, Inc. (NYSE: MAX), based in Los Angeles, has exciting news for its investors and stakeholders. The company is gearing up to announce its financial results for the third quarter of 2024 on an upcoming Wednesday. This announcement will take place after the market closes, providing important insights into the...

Continue Reading
Understanding Recent Trends in Canadian Stocks and Markets

Updated Category News Views 329

Canadian Stock Market Overview Recently, the Canadian stock market experienced a decline, reflecting a challenging trading environment. The decline was multifaceted, with notable tumbles in sectors such as the Consumer Staples, REITs, and Healthcare, which significantly influenced overall market performance. Investors and analysts are keenly observing these fluctuations,...

Continue Reading
Discover Key Trends in Network Observability for IT Success

Updated Category News Views 137

Emerging Trends in Network Observability Join experts as they discuss how IT leaders can adapt observability tools to meet modern network challenges. Enterprise Management Associates (EMA) is hosting an insightful webinar titled "Your NetOps Tools Are Aging Faster Than Your Network: 5 Emerging Trends That Are Reshaping Network Observability." Shamus McGillicuddy, Vice...

Continue Reading
Realbotix Secures Payment in Genesis Restructuring Efforts

Updated Category News Views 74

Realbotix Achieves Major Financial Recovery Realbotix Corp. (TSX-V: XBOT | Frankfurt Stock Exchange: 76M0.F | OTC: XBOTF) is making waves in the news by recently securing a significant cash payment of US$743,500 as part of its ongoing restructuring efforts with Genesis Global Capital. This milestone is a positive step for the Company as it works through the challenges of...

Continue Reading
Immedica Pharma's Loargys: Pioneering Hope in Rare Disease

Updated Category News Views 210

Game-Changing Approval or Just Another Hype Train? Time for a gut check: Immedica Pharma just made waves with its Loargys® (pegzilarginase-nbln), snagging accelerated FDA approval for treating hyperargininemia tied to Arginase 1 Deficiency (ARG1-D). So what's the big deal? Well, basically, we're talking about a breakthrough here—it's the first therapy proven to lower...

Continue Reading